We next analyzed CSF proteomic data from GRN haploinsufficiency mutation carriers and noncarrier controls from the ALLFTD consortium to determine whether levels of MERTK and AXL tracked with presymptomatic and symptomatic stages of GRN-FTD. Here, CSF2 is linked to frontotemporal dementia.